Current Challenges in the Development of Platelet-Rich Plasma-Based Therapies.


Journal

BioMed research international
ISSN: 2314-6141
Titre abrégé: Biomed Res Int
Pays: United States
ID NLM: 101600173

Informations de publication

Date de publication:
2024
Historique:
received: 21 02 2024
revised: 15 05 2024
accepted: 21 06 2024
medline: 19 8 2024
pubmed: 19 8 2024
entrez: 19 8 2024
Statut: epublish

Résumé

Nowadays, biological therapies are booming and more of these formulations are coming to the market. Platelet-rich plasma, or PRP, is one of the most widely used biological therapies due to its ease of obtention and autologous character. Most of the techniques to obtain PRP are focusing on new processes and methods of optimization. However, not enough consideration is being given to modify the molecular components of PRP to generate more effective formulations with the aim of improving PRP treatments. Therefore, this review covers different novel PRP-obtaining methods that attempt to modify the molecular composition of the plasma.

Identifiants

pubmed: 39157212
doi: 10.1155/2024/6444120
pmc: PMC11329313
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

6444120

Informations de copyright

Copyright © 2024 Jon Mercader-Ruiz et al.

Déclaration de conflit d'intérêts

The authors declare no conflicts of interest.

Auteurs

Jon Mercader-Ruiz (J)

Microfluidics Cluster UPV/EHU BIOMICs Microfluidics Group Lascaray Research Center University of the Basque Country UPV/EHU 01006, Vitoria-Gasteiz, Spain.
Advance Biological Therapy Unit Hospital Vithas Vitoria 01008, Vitoria-Gasteiz, Spain.

Maider Beitia (M)

Advance Biological Therapy Unit Hospital Vithas Vitoria 01008, Vitoria-Gasteiz, Spain.

Diego Delgado (D)

Advance Biological Therapy Unit Hospital Vithas Vitoria 01008, Vitoria-Gasteiz, Spain.

Pello Sánchez (P)

Advance Biological Therapy Unit Hospital Vithas Vitoria 01008, Vitoria-Gasteiz, Spain.
Arthroscopic Surgery Unit Hospital Vithas Vitoria 01008, Vitoria-Gasteiz, Spain.

Begoña Porras (B)

Arthroscopic Surgery Unit Hospital Vithas Vitoria 01008, Vitoria-Gasteiz, Spain.

Irene Gimeno (I)

Advance Biological Therapy Unit Hospital Vithas Vitoria 01008, Vitoria-Gasteiz, Spain.

Sergio González (S)

Arthroscopic Surgery Unit Hospital Vithas Vitoria 01008, Vitoria-Gasteiz, Spain.

Fernando Benito-Lopez (F)

Microfluidics Cluster UPV/EHU Analytical Microsystems & Materials for Lab-on-a-Chip (AMMa-LOAC) Group Analytical Chemistry Department University of the Basque Country UPV/EHU 48940, Leioa, Spain.

Lourdes Basabe-Desmonts (L)

Microfluidics Cluster UPV/EHU BIOMICs Microfluidics Group Lascaray Research Center University of the Basque Country UPV/EHU 01006, Vitoria-Gasteiz, Spain.
Basque Foundation of Science IKERBASQUE 48009, Bilbao, Spain.

Mikel Sánchez (M)

Advance Biological Therapy Unit Hospital Vithas Vitoria 01008, Vitoria-Gasteiz, Spain.
Arthroscopic Surgery Unit Hospital Vithas Vitoria 01008, Vitoria-Gasteiz, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH